Insight Molecular Diagnostics (IMDX) Current Assets (2015 - 2026)

Insight Molecular Diagnostics has reported Current Assets for 12 years, with the latest figure at $30.5 million in Q1 2026.

• Quarterly Current Assets fell 15.85% year-over-year to $30.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $30.5 million (down 15.85% YoY) and the FY2025 annual result came in at $15.3 million, up 30.16% from the prior year.
• Current Assets grew to $30.5 million in Q1 2026 per IMDX's latest filing, from $15.3 million in the prior quarter.
• Over five years, Current Assets peaked at $49.4 million in Q2 2022 and troughed at $4.8 million in Q3 2024.
• A 5-year average of $21.4 million and a median of $21.0 million in 2023 frame the typical range for Current Assets.
• The sharpest annual moves came in 2024 and 2025: Current Assets tumbled 71.67% in 2024, then surged 454.9% in 2025.
• Over 5 years, Current Assets stood at $25.5 million in 2022, then slumped by 58.11% to $10.7 million in 2023, then gained by 9.92% to $11.8 million in 2024, then soared by 30.16% to $15.3 million in 2025, then jumped by 99.38% to $30.5 million in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $30.5 million, $15.3 million, and $21.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.